Introduction {#section9-0269215520911970}
============

Deforming spastic paresis involves both muscular and neural mechanisms that lead to hypo-extensibility and muscle overactivity in antagonist muscles and to reduced motor command on agonist muscles.^[@bibr1-0269215520911970],[@bibr2-0269215520911970]^ Consequently, paretic patients experience impairments in active range of movement, which are often associated with limitations in functional activities of daily life and restricted mobility.^[@bibr3-0269215520911970]^

Much of the existing literature on focal interventions for the improvement of spastic paresis has focused, and often continues to focus, on ordinal measurements of resistance to passive movement: the most popular tools being Ashworth-derived scales.^[@bibr4-0269215520911970],[@bibr5-0269215520911970]^ However, these subjective, unquantified, passive resistance measures lack clinical relevance when it comes to understanding whether substantial changes in active capacities and functioning have occurred after treatment.^[@bibr6-0269215520911970][@bibr7-0269215520911970]--[@bibr8-0269215520911970]^

Motor impairment in patients with spastic paresis is governed primarily by the degree of antagonist resistance around not just a single joint but multiple joints in the affected limb;^[@bibr1-0269215520911970]^ therefore, attempts at active movement are hindered in particular by antagonistic spastic cocontraction from several muscles.^[@bibr9-0269215520911970]^ This symptom is overlooked in assessments of resistance to passive movements and in measures of active movements at a single joint.^[@bibr9-0269215520911970]^ A composite measure of active range of motion may therefore be a more functionally relevant tool to estimate active movement capacities. To the best of our knowledge, there are no published data describing a composite active range of motion measurement, nor data to show correlations between this measure and improvements in active function.

Results of two recent Phase 3, randomized, double-blind studies and their open-label extensions conducted in adults with chronic spastic paresis of the upper or lower limb demonstrated improvements in range of active motion and gains in active function following repeat injections of botulinum toxin type A compared with placebo.^[@bibr10-0269215520911970][@bibr11-0269215520911970]--[@bibr12-0269215520911970]^ Using data from these two studies, we evaluated a novel composite measure of active range of motion and determined whether changes in this measure correlated with changes in active function following repeated treatment with botulinum toxin type A.

Methods {#section10-0269215520911970}
=======

We performed a post hoc analysis of two randomized, placebo-controlled, Phase 3, double-blind studies (upper limb: NCT01313299;^[@bibr10-0269215520911970]^ lower limb: NCT01249404^[@bibr12-0269215520911970]^) and their open-label extensions (NCT01313312 and NCT01251367,^[@bibr11-0269215520911970],[@bibr12-0269215520911970]^ respectively) exploring the effects of abobotulinumtoxinA (Dysport^®^, Ipsen Biopharm Ltd, Wrexham, UK) in subjects with chronic hemiparesis. The objectives of this study were to evaluate the sensitivity to change and the correlation with active function of a novel composite measure of active range of motion (X~A~), for assessing change in global active range of motion in patients with upper or lower limb spastic paresis over repeated treatment cycles.

Full details of the protocols for the original upper limb^[@bibr10-0269215520911970],[@bibr11-0269215520911970]^ and lower limb^[@bibr12-0269215520911970]^ studies, including eligibility criteria, study interventions, and assessments, have been previously published. In brief, eligible patients were aged between 18 and 80 years and had spastic hemiparesis following one clinically defined stroke episode or brain trauma ⩾6 months prior to enrollment. Key exclusion criteria included major limitations in passive range of motion in the affected limb, physiotherapy initiated less than four weeks before expected enrollment, or treatment with botulinum toxin type A of any type in the previous four months. Patients could receive up to five treatment cycles with abobotulinumtoxinA, inclusive of the initial double-blind, randomized, placebo-controlled treatment cycle. Dosing during the open-label treatment cycles was at the investigator's discretion, up to a maximum of 1500 U. In all studies, patients attended mandatory follow-up visits at Weeks 4 and 12 of each treatment cycle, with discretionary visits at Weeks 16, 20, and 24. Retreatment was possible on or after Week 12 of each cycle. Maximum study duration for patients completing both double-blind and open-label studies was 18 months.

The key assessment used in this post hoc analysis was the composite active range of motion, or CX~A~, which was defined as follows: upper limb CX~A~ = X~A~ for elbow flexors + X~A~ for wrist flexors + X~A~ for extrinsic finger flexors; lower limb CX~A~ = X~A~ for soleus + X~A~ for gastrocnemius muscles. Each of these muscle groups was included in the calculation regardless of whether the muscle groups were injected or not. For a given antagonist, X~A~ is the maximal active range of motion against the resistance of this antagonist, reflecting the net result, in terms of joint angles, of the force developed by the command reaching the agonist, minus the passive (stiffness) and active (spastic cocontraction) antagonist resistances over a single movement.^[@bibr1-0269215520911970],[@bibr13-0269215520911970]^ Assessment of X~A~ followed the measurement procedures described by Gracies and colleagues.^[@bibr1-0269215520911970],[@bibr13-0269215520911970]^ For each antagonist tested, X~A~ was measured by goniometry, using zero angle as the theoretical position of minimal stretch of the antagonist assessed.^[@bibr1-0269215520911970],[@bibr13-0269215520911970]^ Measurements were taken in a seated position for the upper limb and in supine position for the lower limb. The X~A~ measures have shown intra- and inter-rater reliability in the muscles evaluated in the present study.^[@bibr14-0269215520911970]^

Active upper limb function was assessed using the Modified Frenchay Scale,^[@bibr13-0269215520911970],[@bibr15-0269215520911970],[@bibr16-0269215520911970]^ a modified version of the original Frenchay Arm Test.^[@bibr17-0269215520911970]^ The Modified Frenchay Scale measures active upper limb function in hemiparesis based on a video review of 10 everyday living tasks.^[@bibr15-0269215520911970]^ Six tasks are bimanual and four are unimanual with the paretic hand. Each task is rated on a 10 point visual analog scale by independent assessors (0 = *no movement* to 10 = *normal movement*; 5 = *task barely accomplished*). Active lower limb function was measured using the 10-m walking speed test at comfortable and maximal walking speeds without walking aids, while wearing shoes and while barefoot. In the present analysis, comfortable barefoot walking speed data were used.

Study populations included in this analysis were the intention-to-treat populations for each study, defined as all patients who received at least one injection of study medication. Efficacy analyses were recorded as the mean ± standard deviation and 95% confidence interval of change from baseline to Week 4 (post-injection) for double-blind cycles for CX~A~, and to Weeks 4 and 12 (post-injection) of open-label treatment cycles for CX~A~ and measures of function. All open-label analyses for CX~A~ and measures of function included only subgroups of patients with data available for both Week 4 and Week 12 of each treatment cycle (Cycles 1--3 only, as *n* = 0 at Cycle 4 Week 12). Baseline values were considered to be Day 1 (prior to injection) of the double-blind phase. Analyses were performed by treatment group in the double-blind phase (placebo vs. abobotulinumtoxinA) and for all patients in the open-label extension (all doses combined). Linear relationships between CX~A~ and measures of function were explored using Pearson's correlation coefficients on changes from baseline to Weeks 4 and 12 of open-label treatment cycles for all patients with data available (Cycles 1--4).

Results {#section11-0269215520911970}
=======

Patients {#section12-0269215520911970}
--------

In the upper and lower limb open-label studies, 254 and 345 patients, respectively, received repeated injections.^[@bibr10-0269215520911970][@bibr11-0269215520911970]--[@bibr12-0269215520911970]^ The number of patients who received injection in, and completed each cycle is shown in [Figure 1](#fig1-0269215520911970){ref-type="fig"}.^[@bibr10-0269215520911970][@bibr11-0269215520911970]--[@bibr12-0269215520911970]^ Full details of patient flow and of patient demographics, baseline characteristics, and mean dose of abobotulinumtoxinA injected into each of the muscle groups can be found in the original study publications.^[@bibr10-0269215520911970][@bibr11-0269215520911970]--[@bibr12-0269215520911970],[@bibr18-0269215520911970]^ In general, patient demographics and baseline characteristics were similar between studies; across double-blind treatment groups of both studies, the mean age was 51 to 53 years, 62% to 70% of patients were male, and in 83% to 92% of patients, the cause of spastic paresis was stroke. CX~A~ values at baseline of the double-blind study are shown in [Table 1](#table1-0269215520911970){ref-type="table"}. Baseline values for active function at Cycle 1 were a mean \[95% confidence interval\] score of 3.9 \[3.7; 4.1\] out of 10 on the Modified Frenchay Scale and a 10-m comfortable barefoot walking speed of 0.447 \[0.424--0.469\] m/s.

![Patients in the upper and lower limb studies.\
Further details on patient flow and reasons for withdrawal are reported in the primary publications for the upper and lower limb studies.^[@bibr10-0269215520911970][@bibr11-0269215520911970]--[@bibr12-0269215520911970]^\
^a^Includes 223 patients from the double-blind study and 31 newly recruited patients.](10.1177_0269215520911970-fig1){#fig1-0269215520911970}

###### 

Change from baseline in composite active range of motion during the upper limb and lower limb double-blind studies.

![](10.1177_0269215520911970-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------
  Time point                              Upper limb              Lower limb                                      
  --------------------------------------- ----------------------- ----------------------- ----------------------- -----------------------
  Baseline (*n*)\                         58\                     133\                    128\                    253\
  Mean \[95% CI\]                         302.1 \[30.0; 540.0\]   294.4 \[70.0; 540.0\]   150.7 \[95.0; 210.0\]   149.9 \[80.0; 220.0\]

  Change from baseline to Week 4 (*n*)\   55\                     128\                    127\                    253\
  Mean \[95% CI\]                         5.5 \[−5.0; 15.9\]      36.6 \[27.7; 45.4\]     4.4 \[1.5; 7.2\]        6.3 \[4.3; 8.3\]
  ---------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; *n*: number of patients with data available.

Data are for double-blind intention-to-treat populations. Data are presented in degrees (°).

Change in composite range of active motion (CX~A~) {#section13-0269215520911970}
--------------------------------------------------

In the upper limb double-blind trial, mean change in CX~A~ from baseline to Week 4 was markedly greater following abobotulinumtoxinA injection (doses pooled) than following placebo injection, in contrast with results from the lower limb double-blind trial ([Table 1](#table1-0269215520911970){ref-type="table"}).

In the open-label extension studies, there were sustained improvements in CX~A~ across Cycles 1 to 3 at Weeks 4 and 12 in both the upper and lower limb trials (doses pooled; [Figure 2(a)](#fig2-0269215520911970){ref-type="fig"} and ([b](#fig2-0269215520911970){ref-type="fig"})), except from Cycle 2 to Cycle 3 where the number of remaining patients in the trial was markedly reduced. Results were not analyzed for Cycle 4 as patient numbers were too low. During both the upper and lower limb studies, mean change in CX~A~ was numerically higher at Week 4 of each cycle compared with Week 12.

![Change from baseline to Week 4 and Week 12 in (a) upper limb CX~A~, (b) lower limb CX~A~, (c) upper limb active function, and (d) lower limb active function, during the open-label extension studies.\
CX~A~: composite active range of motion; MFS: Modified Frenchay Scale; *n*: number of patients with data at both Week 4 and Week 12 of each cycle.\
Data are presented as mean \[95% confidence interval\]. Active function was assessed by the MFS (upper limb) and unaided comfortable barefoot walking speed (lower limb).](10.1177_0269215520911970-fig2){#fig2-0269215520911970}

Change in active function {#section14-0269215520911970}
-------------------------

Patients receiving repeated abobotulinumtoxinA injections during the open-label extension studies showed improvements in active function following treatment. At Week 4, mean improvements from baseline in upper limb active function (Modified Frenchay Scale score) increased between Cycles 1 and 2, then decreased slightly during Cycle 3 ([Figure 2(c)](#fig2-0269215520911970){ref-type="fig"}). At Week 12, improvements in active function were numerically greater than they were at Week 4, and this effect was consistent across cycles ([Figure 2(c)](#fig2-0269215520911970){ref-type="fig"}). Similarly, in the lower limb study, improvements in comfortable barefoot walking speed were maintained across open-label treatment cycles at Weeks 4 and 12, with consistently higher improvements observed at Week 12 than at Week 4 ([Figure 2(d)](#fig2-0269215520911970){ref-type="fig"}).

Correlations between CX~A~ and functional outcomes {#section15-0269215520911970}
--------------------------------------------------

As shown in [Figure 3](#fig3-0269215520911970){ref-type="fig"} and [Table 2](#table2-0269215520911970){ref-type="table"}, there were correlations between absolute values for CX~A~ and measures of active function in the upper limb (*P* \< 0.0001--0.0004) and lower limb (*P* \< 0.0001--0.0284) at Week 4 and Week 12 of each open-label cycle. Although significant, these correlations were weak to moderate (*r* = 0.186--0.636).

![Scatterplot and correlation analysis for CX~A~ and active function at Week 12 of Cycle 1 in (a) upper limb and (b) lower limb.\
CX~A~: composite active range of motion; MFS: Modified Frenchay Scale; *n*: number of patients with data available.\
Data are presented as absolute values.](10.1177_0269215520911970-fig3){#fig3-0269215520911970}

###### 

Relationship between composite active range of motion and measures of active function in the upper and lower limb studies (absolute values and changes from baseline).

![](10.1177_0269215520911970-table2)

  Time point                 Upper limb study   Lower limb study                                                      
  -------------------------- ------------------ ------------------ ---------- -------- ---------- -------- ---------- --------
  Cycle 1 (*n*)              179                170                161        152      335        334      317        316
   Correlation coefficient   0.575              0.052              0.621      0.122    0.221      −0.036   0.274      −0.021
   *P* value                 \<0.0001           0.5007             \<0.0001   0.1331   \<0.0001   0.5158   \<0.0001   0.7052
  Cycle 2 (*n*)              158                148                137        128      286        285      252        252
   Correlation coefficient   0.601              0.155              0.608      0.213    0.222      −0.052   0.211      −0.065
   *P* value                 \<0.0001           0.0601             \<0.0001   0.0160   0.0001     0.3854   0.0008     0.3059
  Cycle 3 (*n*)              104                98                 53         50       215        215      150        150
   Correlation coefficient   0.636              0.296              0.476      0.059    0.186      −0.086   0.285      0.021
   *P* value                 \<0.0001           0.0031             0.0003     0.6819   0.0064     0.2076   0.0004     0.8029
  Cycle 4 (*n*)              46                 43                 0          0        134        134      0          0
   Correlation coefficient   0.503              0.150              --         --       0.189      −0.025   --         --
   *P* value                 0.0004             0.3367             --         --       0.0284     0.7785   --         --

*n*: number of patients with data available.

Linear relationships analyzed using the Pearson correlation coefficient on absolute values and changes from baseline.

Correlations between changes from baseline in CX~A~ and in active function were significant only at open-label Cycle 2 Week 12 (*P* = 0.0160) and Cycle 3 Week 4 (*P* = 0.0031) of the upper limb study.

Discussion {#section16-0269215520911970}
==========

This post hoc analysis of recent double-blind and open-label extension studies of abobotulinumtoxinA in chronic spastic paresis showed significant, albeit moderate, correlations between CX~A~ (composite active range of motion) and active function in the upper and lower limbs. This analysis also showed that changes in CX~A~ and active function after abobotulinumtoxinA therapy followed a different time course, such that improvements in CX~A~ peaked at Week 4 post-injection, whereas improvements in active function peaked at Week 12. Finally, we showed that CX~A~ was sensitive to change following treatment for upper and lower limb spastic paresis. The pattern of changes in CX~A~, which showed an overall trend toward greater improvements with repeated treatment cycles followed by a plateau at later cycles, reflects the results observed for other outcome measures of the original studies.^[@bibr10-0269215520911970][@bibr11-0269215520911970]--[@bibr12-0269215520911970]^

Historically, composite outcome measures used in rehabilitation studies have tended to be generated from passive resistance measures, for example, by summing modified Ashworth Scale scores of multiple joints to assess muscle tone changes in the affected limb.^[@bibr18-0269215520911970][@bibr19-0269215520911970][@bibr20-0269215520911970][@bibr21-0269215520911970][@bibr22-0269215520911970][@bibr23-0269215520911970][@bibr24-0269215520911970][@bibr25-0269215520911970][@bibr26-0269215520911970][@bibr27-0269215520911970][@bibr28-0269215520911970][@bibr29-0269215520911970]--[@bibr30-0269215520911970]^ Although helpful, these approaches have overlooked assessment of active motion or active function. A "composite functional index" has been developed, which assesses perceived function involving mostly passive movements.^[@bibr31-0269215520911970]^ This index combined subjective assessments (ease of cleaning palm, cutting fingernails, and putting arm through sleeve) with Barthel Index items (grooming, feeding, and dressing), but true active function, such as that assessed via the Modified Frenchay Scale, was not explored.^[@bibr31-0269215520911970]^

In the present study, a trend was observed toward consistently greater improvements in active function at Week 12 compared with Week 4 following injection, although 95% confidence intervals were overlapping. In the lower limb study in particular, change from baseline in comfortable barefoot walking speed was increased at Week 12 of Cycles 1 to 3 compared with Week 4, while this was the opposite for CX~A~ in both the upper and lower limbs. This discrepancy may be due to time required for motor learning processes and improved inter-segment coordination to develop, that is, time needed to acquire new motor control to adjust to the new situation of a weaker and looser antagonist between Weeks 4 and 12 following injection, during which time direct blocking effects of the toxin on antagonist cocontractions start declining.^[@bibr10-0269215520911970][@bibr11-0269215520911970]--[@bibr12-0269215520911970]^ An additional reason could be the window of opportunity to retrain, that is, patients may have walked more and/or used their arm in a more intensive way between Week 4 and Week 12, and therefore increased their activity or their intensity of rehabilitation. This increase in activity may have been sufficient to enhance functional effects of treatment, even when direct effects of the toxin on actual range of active motion diminished. Overall, this observation may indicate that the optimal assessment time of active range of motion following injection may be around Week 4, whereas changes in active function post-injection may be more efficiently assessed around Week 12.

Although this analysis demonstrated a significant correlation between absolute values for CX~A~ and active function in the upper and lower limbs at Weeks 4 and 12 across all treatment cycles, there was no clear correlation between changes from baseline in CX~A~ and active function when explored between both values at the same time point. Again, this may be due to the time lag between maximal change in CX~A~ (Week 4) and maximal change in function (Week 12), which would contribute to lesser correlation between the two than between absolute values of each at a given time.

So far as limitations for the present analysis, CX~A~, particularly when measured on a small number of limb muscles as done here, may not capture all clinically relevant aspects of motor function along the whole limb. In particular, at Week 4, additional limitations of movements may not have been captured (e.g. limitations due to pronator or shoulder extensor overactivity in the upper limb, or due to overactivity in proximal muscles of the lower limb). A further limitation was the relatively short duration of the assessment period evaluated here, as motor commands may require more than 12 weeks to adapt to the effects of a muscle-weakening therapy.

Nevertheless, use of CX~A~ as a marker of active function may provide several benefits over existing measures. Furthermore, X~A~ is easy to learn and use in a clinical setting. With these points in mind, CX~A~ could be a measure of choice to approach overall level of active function in patients with upper or lower limb spasticity. Because the effects of botulinum toxin type A injections have been well established on tone and spasticity reduction, we suggest that either CX~A~ (early) or measures of active function (late) are now used with higher functional relevance as primary or secondary outcome measures for assessing effects of treatment in the paretic upper and lower limbs.

###### Clinical messages

-   A novel composite score of active range of motion correlates with active function in patients with upper or lower limb spastic paresis.

-   Changes in the composite score of active range of motion are associated with active functional improvements observed eight weeks later.
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